Blood test may guide heart failure treatment to cut hospital returns
NCT ID NCT02963272
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
Heart failure is a serious condition with high death and rehospitalization rates. This study tested whether using a blood marker called ST2 to guide treatment could reduce hospital readmissions within one month. Researchers compared standard care with a strategy that adjusts medications based on ST2 levels in 123 hospitalized heart failure patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ST2 biomarker-guided treatment strategy
What this could lead to
If successful, this approach could help doctors personalize heart failure treatment to reduce hospital readmissions and lower healthcare costs.
What could go wrong
This is a small, completed study with 123 participants, so results may not apply to all heart failure patients. The ST2-guided strategy may not significantly reduce readmissions compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Regional Hospital Arnaud de Villeneuve
Montpellier, Languedoc-Roussillon, 34295, France